Tranzyme Pharma Announces Issuance of European Patent Protecting Company’s Macrocyclic Chemistry
News Dec 15, 2006
Tranzyme Pharma has announced the issuance of a European patent entitled “Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery.”
The patent protects key aspects of the Company’s core drug discovery technology, Macrocyclic Template Chemistry (MATCH™).
MATCH™ is based on the synthesis of specific types of low-molecular weight, drug-like compounds called macrocycles.
This European patent, together with the notice of allowance for the corresponding U.S. patent received earlier this year, provides substantial protection for the Company’s chemistry technology.
According to Tranzyme, currently it has approximately 40 patent applications covering MATCH™ as well as its drug candidates for GI and metabolic diseases.
Tranzyme has leveraged MATCH™ to develop first-in-class drug candidates that have shown to be well tolerated in man and have demonstrated oral bioavailability, in vivo efficacy, and potency and selectivity against multiple types of pharmaceutically important targets.
Tranzyme has developed the synthetic library of these macrocyclic compounds which contains 25,000 structures. The MATCH™ library exhibits chemical and conformational diversity to provide broad target applicability in modulating G-protein coupled receptors, protein kinases, protein-protein interactions and ion channels.
“MATCH™ enables Tranzyme to design its macrocyclic compounds to exhibit highly specific recognition of a pharmacological target, which leads to greatly reduced safety issues during development,” said Helmut Thomas, Ph.D., DABT, Senior Vice President of Research & Preclinical Development for Tranzyme Pharma.
“We are able to achieve excellent fit for a biological target by combining recognition elements for multiple pharmacophores in a compact structure.”
“We are very excited with the significant progress that we have made in demonstrating the ability of our chemistry to produce a pipeline of high-quality drug candidates,” added Vipin K. Garg, Ph.D., President & CEO of Tranzyme Pharma.
“Our strategy is to further leverage this technology in joint drug discovery and development alliances across multiple therapeutic areas.”
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE